TrialAssure Announces AI Generative Text Partnership with MMS
TrialAssure announced that it is collaborating with MMS on a new artificial intelligence (AI) initiative aimed at developing generative text specifically for medical writing in the field of drug development.
The primary focus of this collaboration is to utilize AI to generate text specifically tailored for creating plain language summary (PLS) documents. These documents help clinical researchers effectively communicate their findings with patients, families, and the public by presenting the results in a manner that is easily understandable to the average reader.
This initiative will allow the companies to complete an initial draft of a medical writing document more efficiently. Instead of writing sections from scratch, TrialAssure Link will produce the first draft for the medical writer to review and update.
“Our AI solutions experts and SMEs with extensive experience in medical writing and clinical trial-related documents are working together hand-in-hand to develop this new technology that will help shape the future of the pharmaceutical industry,” said Zach Weingarden, director of product solutions, TrialAssure. “The possibilities of AI in this industry are endless, and we are exploring additional use cases that target different aspects of the clinical trial and related documents at various stages.”
Reference
TrialAssure Announces AI Generative Text Partnership with Top Clinical Research Organization MMS on New Medical Writing Initiative. (2023, August 3). TrialAssure.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
